Arriello Group will be present at CPhI Russia, the leading networking event in the Russian and CIS markets that takes place between the 16th and the 17th of April 2014 in St. Petersburg, Russia.
Anna Lukyanova, Chief Operating Officer, will be at the exhibition meeting clients and initiating new partnerships.
If you are attending the event and would like to meet Anna Lukyanova, please do not hesitate to contact us for an appointment. We will be glad to meet you to discuss your projects or areas requiring our expert support.
Contact us for an appointment
How can we help you?
We are a Life Science industry service provider that has evolved around a notion or concept which we refer to as a “Network of Excellence”. We work as a true professional network, as we firmly believe this to be the only honest way to ensure that your projects are delivered by experts within the industry, while offering highly competitive rates.
We cover Regulatory Affairs, Vigilance (Pharmaceuticals and Devices), Medical Writing and Translations. We can handle requirements in Russia and CIS countries like regulatory submissions, translations, vigilance services…
About the event
This years event is the second occasion of CPhI Russia. This content-led exhibition and networking event is co-located with the IPhEb Forum and held from 16-17 April 2014 in Lenexpo, St. Petersburg, Russia.
Hosting a range of exhibitors in the field of pharma ingredients, finished dosage, machinery, equipment, technology and outsourcing, with the aim to initiate business and build partnerships in the booming Russian and CIS pharma markets.
Why attend the event?
CPhI Russia is the gateway to the Russian, CIS and CEE markets.
The Russian market experienced high double-digit growth in recent years and is positioned firmly at the forefront of emerging markets. Russia is currently the eleventh largest pharmaceutical market in the world and is projected to reach a value of US $26.7 billion by 2014.
The Russian Government’s ambitious Pharma 2020 plan, introduced in 2009, includes funding of nearly US$5 billion and seeks to dramatically increase domestic pharmaceutical manufacturing and R&D capabilities.
As a result of the Pharma 2020 plan, the demand for international pharmaceutical ingredients and manufacturing and packaging equipment will be increasing dramatically in order to upgrade existing manufacturing sites to GMP standards.
Specific Pharma 2020 Goals
Increasing domestic finished-dosage manufacturing capacity
Direct investment by the Russian government
Funding of $5 Billion